DEPARTMENT OF HEALTH AND HUMANSERVICES Food and Drug Administration

Indications for Use

Form Approved: 0MB No. 0910-0120

Expiration Date: 06/30/2023 See PRA Statement below.

510(k) Number *(if known)* BK210632/0

Device Name

Royal MAXXTM PRP Concentration System

Indications for Use (Describe)

The Royal MAXX PRP Concentration System is designed to be used at the patient's point of care for the safe and rapid preparation of a platelet rich plasma (PRP) from a small sample of a mixture of peripheral blood and bone marrow aspirate that is mixed with autograft and or allograft bone prior to application to a bony defect for improving handling characteristics.

Type of Use (Select one or both, as applicable)

IZI Prescription Use (Part 21 CFR 801 Subpart D)

D Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid 0MB number."